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Abstract
Background: Protoporphyria (PP) resulting from two rare, inherited diseases of heme biosynthesis leads to dermal 
phototoxicity by accumulation of the heme precursor protoporphyrin IX. No standardized tools to quantify the degree 
of PP-related phototoxicity and its change by medical intervention have been published.
Methods: Results from a questionnaire completed by 17 affected individuals were used to determine the relative 
importance of two main components of PP-related phototoxicity, skin pain and sunlight exposure time, with respect to 
the effectiveness of any particular medical treatment.
Results: Inter-rater reliability was 0.71 (n = 490), repeated estimates by four identical individuals showed high 
reproducibility (Slope = 1, intercept = 0, n = 136, Passing-Bablock).
Six different models were developed, three of them showed good correlation with effectiveness estimates. Data from
an unpublished trial indicated that the model with highest potential of responsiveness was the so called "Exposure
times [multiplied by] Freedom from Pain" (ETFP). The minimal clinically important difference (MID) was 15 (10.2-20.4)
ETFP scores, representing 28% of the standard deviation of the clinical trial data and 2.9% of its total range.
Conclusions: Among the six models proposed to assess the effectiveness of therapeutic interventions in PP the ETFP 
model demonstrates the highest sensitivity using the existing data from a clinical trial of afamelanotide in PP. The 
results of this study have provided sufficient validation of the ETFP model that is likely to prove useful in future clinical 
trials.
Background
Erythropoietic protoporphyria (EPP, OMIM 177000), a
rare inherited disease of heme biosynthesis, is due to
mutations of the enzyme ferrochelatase that catalyzes the
ultimate step in heme biosynthesis, the insertion of iron
into protoporphyrin IX to form heme [1,2]. Recently, a
new disease entity, X-linked protoporphyria (XLDPT;
OMIM 300752), which is caused by an over-activity of
aminolevulinic acid synthase 2 due to specific mutations
in its C-terminal region has been described [2,3]. Proto-
porphyria (PP) refers to both EPP and XLDPT in this
article. The main symptom, dermal phototoxicity, is iden-
tical in both diseases, as they both lead to an accumula-
tion of the ferrochelatase substrate, photosensitizing
protoporphyrin IX. The accumulated protoporphyrin is
composed of two fractions, zinc-protoporphyrin and
(metal-)free protoporphyrin. Patients with XLDPT show
a higher proportion of zinc-protoporphyrin than those
with EPP. As zinc-protoporphyrin does not induce photo-
toxicity [4,5], patients with XLDPT may exhibit less pho-
totoxicity than classical PP patients at the same level of
total erythrocytic protoporphyrin. Due to the hydropho-
bicity of protoporphyrin, excess protoporphyrin is elimi-
nated only by the biliary route. In about 1-4% of PP
patients a protoporphyrin-induced liver failure develops,
heralded by increasing erythrocytic protoporphyrin lev-
els and concomitant increment in phototoxicity [6].
Light-induced phototoxic reactions in PP are of vari-
able severity: Immediately or within a few minutes of
sunlight-exposure, PP-patients feel stinging pain in sun-
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exposed skin that disappears upon termination of light-
exposure. On prolonged exposure, erythema, edema and
skin lesions may develop and an incapacitating pain may
occur. The pain cannot be alleviated by pain killers such
as acetaminophen or salicylic acid derivatives. Even non-
steroidal-anti-rheumatics are ineffective. The severity of
phenotype is related to erythrocytic or plasma protopor-
phyrin levels [7].
Our recent systematic literature review on treatment
options of dermal phototoxicity in protoporphyria (PP)
showed that available publications are of insufficient
quality to prove efficacy of any treatments that have been
proposed to date [8]. A major problem revealed by this
study was the lack of a standardized efficacy assessment.
Consequently, diverse assessment techniques were
applied among different studies which made it difficult to
compare their results.
Dermal phototoxicity in PP is largely a subjective per-
ception because initial symptoms are rarely accompanied
by physical signs. An optimal measure of subjective
symptoms is the recording of patients' experience [9-11].
Tools for such purposes have been named 'patient
recorded outcome' (PRO) determinations. They are fre-
quently, but not exclusively, designed in the form of ques-
tionnaires. Recently published guidelines and articles
have defined the necessary scientific quality of PRO's[12-
14]. Generalized and standardized tools such as SF36
with documentation of these requirements are available.
But often they do not target specific symptoms of a par-
ticular disease resulting in a low sensitivity in detecting
important treatment-induced changes [15]. Therefore, in
many instances disease-specific PRO's have been applied
[16]. The most frequently used PRO in dermatological
diseases is the 'dermatological quality of life index'
(DLQI). This well documented tool [17] has also been
applied in measuring the life quality in PP[7], but it never
has been used to evaluate the effect of treatment during
the acute phase of PP.
The scientific value of a disease-specific PRO is depen-
dent on the following criteria: Rationale for choosing
selected endpoints, documentation of psychometric
characteristics (content and construct validity, reliability
and responsiveness) and interpretation guidelines includ-
ing minimal important difference [18]. Evaluations of
some of these criteria require the availability of a docu-
mented effective treatment, which is not available in PP
[8]. Here, we propose a PRO instrument for the therapeu-
tic evaluation of dermal phototoxicity in PP.
Methods
Data source
Three different information sources for development and
verification of various models were used: (1) a systematic
review on treatment options of dermal phototoxicity in
erythropoietic protoporphyria rendered information on
possible items reflecting the severity of phototoxicity (2)
a questionnaire described below for the construction of
an optimized model (3) unpublished data from a trial of
afamelanotide in PP (Trial No ACTRN12607000261415)
for checking additional aspects of the model. This work
was conducted according to the Declaration of Helsinki
and has been approved by the institutional and cantonal
ethics review board (Ethik-Kommission der beiden
Zürcher Stadtspitäler, STZ 07/07).
Rational for choosing endpoints
As stated in the Introduction, skin pain of variable inten-
sity is the main symptom of PP-related phototoxicity.
Conditioned by their immediate pain reaction upon sun-
light-exposure and by their life-long experience of the
incapacitating pain from severe phototoxic reactions,
adult PP-patients are often able to anticipate the impend-
ing risk of phototoxicity depending on the actual weather.
In case of presumed high risk of phototoxicity, patients
tend to avoid sunlight exposure as much as possible. If
sunlight-avoidance is strictly followed, patients no longer
suffer from phototoxicity, but the disease markedly limits
outdoor-activities and activities in rooms lit by direct
sunlight and thus, it affects social and working capabili-
ties of the patients.
A PRO to determine PP-related phototoxicity contains
therefore two components: pain and sunlight exposure. A
daily recording of both pain intensity and sunlight expo-
sure time reflects the actual functioning of the patient.
The two components, pain and sunlight exposure inter-
act with each other, as patients suffering from pain will
decrease their sunlight exposure and patients who extend
their sunlight exposure will increase their risk of pain. A
tool was therefore developed to include both components
and was tested for its ability in documenting the effect of
a medical treatment on acute disease activity in PP.
Content validity
For content validity, patients and clinicians should be
involved in identifying and confirming the content of
m e a s u r e .  H e r e ,  w e  r e l i e d  o n  t h e  i n f o r m a t i o n  o b t a i n e d
from a systematic review on therapeutic studies in PP and
the tools used in these studies to assess effectiveness [8]:
Both pain intensity and time of light tolerance were the
efficacy measurements used with light tolerance being
the preferred endpoint.
Construction of a model
Construct validity refers to the degree to which the mea-
sure reflects what it is supposed to measure rather than
something else. In the case of PP, the goal was to con-
struct a model that enables a reliable quantitative mea-
sure of the construct 'PP-related dermal phototoxicity' forMinder et al. Health and Quality of Life Outcomes 2010, 8:60
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the purpose of determination of the effectiveness of med-
ical interventions.
The model required the establishment of a relationship
between the effectiveness of a particular medical inter-
vention and the phototoxicity score. As outlined above,
time of sunlight tolerance and pain intensity are the two
main and interdependent factors in PP-related phototox-
icity. Due to the subjective nature of phototoxicity, only
PP-affected persons can define the relative importance of
these two factors for their well-being. To quantify the rel-
ative weight of both factors, a questionnaire was devel-
oped and sent to 27 affected persons. An estimate of
effectiveness of any particular medical treatment was
requested if, after variable sunlight exposure, a specified
pain intensity resulted. The proposed sunlight exposures
were 15 min, 30 min, 1 hour, 3 hours, 6 hours, 10 hours
and 12 hours. Under each of these exposure times, pain
intensities of none, mild, moderate, severe and intolerable
were separately listed (table 1). For each position, the
effectiveness of any particular medical treatment was
estimated on a scale of 0 and 100%. An environmental
condition to which estimates apply the season and the
daytime with highest phototoxic risk was defined.
Only 7 questionnaires were correctly filled in and par-
ticipants mentioned that the questionnaire was difficult
to understand. Therefore 12 of the initially addressed 27
individuals received additional explanations by the inter-
viewer (EIM) during a regular a medical visit. Care was
taken not to influence the estimates by highlighting the
intended context only. Ultimately, 17 PP-patients felt suf-
ficiently at their ease to answer each of the 35 lines in the
questionnaire, resulting in a total of 490 estimates.
Using an 11-point Lickert scale as a reference, pain
intensities were converted into pain scores so that no
pain equaled to 0, mild to 2, moderate to 5, severe to 8
and intolerable to 10 scores, respectively. Sunlight expo-
sure times were converted in 15-minute blocks. Inter-
rater reliability was assayed by the method of Ebel http://
www.med-ed-online.org/rating/reliability.html, accessed
3rd Aug. 2009).
Reliability
Reliability refers to the consistency with which an instru-
ment measures a given construct [12] and determines to
what extent an error is present in the instrument [19]. It
has two components: the internal consistency measured
by Cronbach's alpha and test-and-retest reliability or
repeatability [20]. The determination of Cronbach's alpha
requires a multi-item assessment. The patient ratings on
these items are statistically related to each other so as to
estimate the underlying construct, and Cronbach's alpha
is a measure of the statistical relatedness of the items [21].
Cronbach's alpha was calculated from the data of an
unpublished phase III trial of afamelanotide in PP.
Repeatability requires testing and retesting of stable
patients. PP-related phototoxicity occurs in separate
attacks; therefore patients do not exhibit stable symp-
toms. Hence repeatability assessment was replaced by
analyzing the reproducibility of effectiveness estimates
from the same individuals 4 months after the initial
inquiry. The questions were rephrased with "pain intensi-
ties" as the main attribute (first column in table 2) as
opposed to "sunlight exposure time" in the first question-
naire (table 1). For this second assessment, no verbal
explanations were given.
Responsiveness, Minimal important difference (MID)
Responsiveness is determined by evaluating the relation-
ship between changes in clinical or patient-based end-
points and changes in the score [22]. The use of an
unresponsive instrument will result in a failure to demon-
strate statistical and clinical significance regardless of the
true treatment effect [12,23]. The MID has been defined
as the smallest difference in scores of a PRO measure that
is perceived by patients as beneficial or harmful, and that
could lead a clinician to consider a change in treatment
[24]. Thus, a MID represents not only a statistically but
also a clinically significant difference. MID ensures that
the observed difference between treatment groups
exceeds what one might expect based upon measurement
error alone. Distribution-based methods for the assess-
m e n t  o f  M I D  r e l y  o n  b a s e l i n e  v a r i a b i l i t y  o f  b a s e l i n e
scores. As mentioned above, phototoxicity has a high
degree of variability due to its episodic character. There-
fore distribution based methods were considered inap-
propriate. Instead, two anchors were used: A Lickert type
pain scale and a global rating. The MID of a 7-point Lik-
ert-type pain scale is 0.5 points difference [25]. As the
pain score used in this study has 11 points, the MID was
converted to 0.5 *(11/7) or 0.8. The second anchor could
be considered as a type of 'global rating of change'. The
frequency distributions of the effectiveness estimates in
the questionnaires were analyzed. Patients had to make
an estimate on a 101-point effectiveness scale, which can
b e  c o n s i d e r e d  a s  a  c o n t i n u o u s  s c a l e .  I f  s p e c i f i c  v a l u e s
cumulate, the interval of these values was assumed to
reflect the minimal difference in change that patients
consider discernible.
Statistical tools
Statistical tests were performed by Analyse- it- for- excel,
version 2.11, by Vassar Stats http://faculty.vassar.edu/
lowry/VassarStats.html, accessed July-August 2009) or by
inter-rater calculator according to Ebel RL [26]http://Minder et al. Health and Quality of Life Outcomes 2010, 8:60
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www.med-ed-online.org/rating/reliability.html accessed
Aug 2009). Stata version 10 was used.
Results
Construction of a model based on questionnaires
Inter-rater reliability of effectiveness estimates
Inter-rater reliability was calculated among 17 individuals
who filled out the 35-line questionnaire. The reliability
for a score was 0.71 based on one rater. Both, pain and
exposure time independently influenced the effectiveness
estimates (Fig 1). As expected, the less the pain and the
longer the exposure time, the higher were the effective-
ness estimates.
Repeatability of effectiveness estimates
Four out of the 17 patients provided a second estimate.
The repeated estimates showed a good repeatability
(Spearman's rs = 0.82) and the Passing-Bablok test
showed a high degree of reproducibility (intercept = 0,
slope = 1; Fig 2), the 95% confidence intervals overlap
with the regression line in the graph. This finding con-
firms the good rater reliability.
Contribution of phototoxicity components to effectiveness 
estimates
Both phototoxicity components, pain intensity and sun-
light exposure time, correlated with the effectiveness esti-
mate of patients (Spearman's rs -0.73 for pain intensity
and 0.36 for sunlight exposure time). The variable pain
intensity measured on a Lickert type scale was called
either "pain" or "pain score". Sunlight exposure time was
named either "exposure time" or "exposure". The effec-
tiveness estimate was used as the independent variable
w i t h  p a i n  i n t e n s i t y  o r  s u n l i g h t  e x p o s u r e  t i m e  a s  t h e
dependent variables. As expected, pain correlated
inversely and sunlight exposure time correlated directly
Table 1: Questionnaire A: Please estimate the minimal effectiveness of a particular medical treatment for EPP in percent 
between 0 and 100.
Exposure Pain reaction % Effectiveness (between 0 and 100)
After 12 hours sunlight exposure: 1.1. You suffer from intolerable pain
1.2. You suffer from strong pain
1.3. You suffer from moderate pain
1.4. You suffer from mild pain
1.5. You don't suffer from pain
After 10 hours sunlight exposure: 2.1. You suffer from intolerable pain
2.2. You suffer from strong pain
....After 6, 3, 1 hour, 30 minutes...
After 15 minutes sunlight exposure: 7.1. You suffer from intolerable pain
7.2. You suffer from strong pain
7.3. You suffer from moderate pain
7.4. You suffer from mild pain
7.5. You don't suffer from pain
During summer time (season of the highest risk) you expose yourself to the sun and afterwards you have a reaction specified belowMinder et al. Health and Quality of Life Outcomes 2010, 8:60
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with effectiveness (data not shown). The different direc-
tions of correlation required to first invert the direction
of one of the two components so that both components
were in the same direction, and then to combine the two
components into a single score i.e. either sum or product.
The following conversions were performed: 'freedom
from pain' was defined as 10 minus pain score, 'sun avoid-
ance' was defined as 13 hours minus sun exposure time in
15-min blocks. The scale of 'freedom from pain' ranged
from minimum 0 to maximum 10 scores, where zero
meant intolerable pain and 10 means no pain; that of
'sunlight avoidance' ranged maximum 52 to minimum 0,
where 52 meant no sunlight exposure and 0 means 13
hours of sunlight exposure within a day.
Five different models each comprised of two compo-
nents, pain intensity and sunlight exposure, were tested
Table 2: Questionnaire B: Please estimate the minimal effectiveness of a hypothetical medical treatment for EPP in 
percent between 0 and 100.
Pain reaction Exposure % Effectiveness (between 0 and 100)
You suffer from intolerable pain: 1.1. After 12 hours of sunlight exposure
1.2. After 10 hours of sunlight exposure
1.1. After 6 hours of sunlight exposure
1.2. After 3 hours of sunlight exposure
1.1. After 1 hour of sunlight exposure
1.2. After 30 minutes of sunlight exposure
1.1. After 30 minutes of sunlight exposure
You suffer from strong pain: 2.1. After 12 hours of sunlight exposure
2.2. After 10 hours of sunlight exposure
....you suffer from moderate pain; you suffer from mild pain...
You don't suffer from pain: 5.1. After 12 hours of sunlight exposure
5.2. After 10 hours of sunlight exposure
5.3. After 6 hours of sunlight exposure
5.4. After 3 hours of sunlight exposure
5.5. After 1 hour of sunlight exposure
5.6 After 30 minutes of sunlight exposure
5.7 After 15 minutes of sunlight exposure
During summer time (season of the highest risk) you expose yourself to the sun and afterwards you have a reaction specified belowMinder et al. Health and Quality of Life Outcomes 2010, 8:60
http://www.hqlo.com/content/8/1/60
Page 6 of 13
for correlation with estimated efficacy by both linear
regression analysis and the Spearman's correlation (table
3). In the formulas below, 'P' represents variable pain
(intensity or score), 'E' represents variable (sunlight)
exposure time.
• Model 1: P/E = Pain intensity Divided by sun Expo-
sure time (PDE).
• Model 2: E*(10 - P) = Exposure time times Freedom 
from Pain (ETFP, fig. 3).
• Model 3: P*(52 - E) = Pain times Sun Avoidance 
(PTSA).
• Model 4: E+ (10 - P) = Sum of Exposure time plus 
Freedom of Pain (SE&FP).
• Model 5: (52-E) + P = Sum of Sun Avoidance plus 
Pain (SA&P).
All five models were significantly correlated with esti-
mated efficacy, p < 0.0001. PDE, SE&FP and SA&P
showed less correlation with effectiveness estimates than
PTSA and ETFP (table 3). Whereas the models with
either multiplication or division were independent from
the relative scales of the items (PDE, ETFP and PTSA),
the models using sum of items were not order-invariant
(SE&FP, SA&P).
Models 2 to 5 can be expressed by the same formula M
= a +b*sunlight exposure + c*pain score +d*sunlight
exposition * pain score. For example, model 2 (ETFP) is
represented by factors a = 0, b = 10, c = 0 and d = -1.
Based on the questionnaire data, the values of a, b, c and
d and their standard errors were estimated by linear
regression as follows: a = 69.5 SE 2.6, b = 0.854 SE 0.103, c
= -7.55 SE 0.43, d = -0.0244 SE 0.0165; r2 = 0.648. This
resulted in
• Model 6: E&P&EP = 69.5 + 0.854 *Exposure -
7.55*Pain score -0.0244 *Exposure * Pain score (fig. 4)
The meaning of PTSA, ETFP and E&P&EP
Scores derived from multiplications are less intuitively
understandable than those derived from additions. To
illustrate these abstract tools, the relations pain and expo-
sure time in ETFP , PTSA or E&P&EP are plotted in fig.
5A, B and 5C separately. The lines displayed represent
identical scores, called iso-scores, for ETFP, PTSA or
E&P&EP, respectively. These figures show that a patient
exposed to sunlight for 4 hours and feeling a pain inten-
sity of 4 has the same ETFP score of 100, as one exposed
for 6 hours and feeling a pain intensity of 6. However, if
after 6 hours of exposure, the patient felt only a pain
Figure 1 The effect of sunlight exposure time and pain on effectiveness estimate. The means of 490 estimates of effectiveness are plotted 
against both pain levels and sunlight exposure time. The pain scores are: 0 = no pain, 2 = mild pain, 5 = moderate pain, 8 = strong pain, 10 = intolerable 
pain. Exposure times are expressed as "multiples of 15 minutes", e.g. 1 = 15 min, 10 = 2.5 hours, 48 = 12 hours etc. The effectiveness ratings are in 
percent between 0 and 100. It is evident, that pain has a higher influence on the effectiveness rating than sunlight exposure time.
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intensity of 2, the ETFP score would be approximately
200. On the other hand, a patient exposed for 6 hours and
feeling a pain intensity of 2 has roughly the same PTSA
score (50) as one exposed for 10 hours and feeling a pain
score of 4. In Model 6 (E&P&EP), nearly straight lines
represent identical scores illustrating that the product
E*P has only a low effect on the model.
These figures show that the power of discrimination in
ETFP is high at long exposure times, as illustrated by the
high number of iso-score lines crossing the horizontal
Figure 2 Repeatability, scatter blot and histogram of residuals according to Passing-Bablok, n = 490 [34]. The variability of the estimates may 
be overestimated in scatter blot. The histogram of residual reveals that many estimates lie close to zero. Consistently, the slope of the diagram is one, 
the intercept zero.
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lines, e.g. the line indicating 10-hour exposure time is
crossed by ETFP iso-score lines from 50 to 400, depend-
ing on the pain intensity. In contrast, PTSA has high dis-
criminating power at shorter exposure times. At a
maximum exposure time of 13 hours, PTSA is indepen-
dent of pain intensity and at long exposure times, differ-
ent pain intensities influence the score only marginally.
As it is unlikely that a patient suffers from severe pain
after short exposure time, it is assumed that the high dis-
criminatory power at low exposure times is of a less prac-
tical importance than that at long exposure times. This
finding implies that ETFP is likely to be more responsive
to treatment effects than PTSA. E&P&EP and ETFP are
similar models except that high pain intensity influences
and depresses ETFP scores more than it does E&P&EP.
Overlay of data from the afamelanotide trial with the
different iso-score line plots showed that most data clus-
tered at the origin of coordinate axes (data not shown).
These data are therefore not informative with respect to
drug efficacy in the clinical trial. Informative data are
those that feature either long exposure and low pain lev-
els or high pain intensities after moderate to long expo-
sures. As ETFP is highly discriminatory for both areas,
ETFP could have some advantage compared to E&P&EP.
However, only the data that are obtained from clinical tri-
als on effective substances will enable the responsiveness
between the two models to be compared.
Estimation of the minimal important difference of ETFP
One anchor to define the MID was the pain score which
correlated linearly with the ETFP score in the data
derived from the questionnaires. A MID of 0.8 on the 11-
point Lickert scale and the correlation between ETFP and
pain were used for the estimation (ETFP = -18.71 × pain-
score+187.1; r2  = 0.28). A MID of 15.0 ETFP-scores
resulted. The second anchor derived from the frequency
distribution of the effectiveness estimates of the patients.
The patients chose between 0 and 100% on a 101-scale.
However, they preferred certain values, as illustrated by a
histogram of the frequency of levels chosen (fig 6). The
s t eps  used we r e  10% or m ult i ples t he r eof  and 5% a t a
lower frequency. Other values were rarely used. Appar-
ently, the patients intuitively felt that they will not per-
ceive a change below five to ten percent of effectiveness.
The range 5-10% effectiveness was projected on the
regression line correlating effectiveness to ETFP (fig. 3;
ETFP = 2.046[effectiveness estimate]). The resulting MID
was 20.5 ETFP scores for the 5% interval and 10.2 for the
10% interval. The MID scores for ETFP estimated by dif-
ferent anchors were comparable, implying an ETFP score
of 5 to 10 can be used as MID. The analogous procedure
performed for the model 6 (E&P&EP) resulted in a MID
of 6.4 for the anchor pain and 15.4 for the 10% and 7.7 for
the 5% effectiveness anchors.
Discussion
A standardized quantitative assessment on PP-related
dermal phototoxicity to analyze effects of therapeutic
interventions has not previously been published. More-
over, experts in the field considered determination of effi-
cacy in PP difficult [27,28].
In this work, models for quantitatively assessing PP-
related dermal phototoxicity were proposed. It was not
Table 3: Correlation of the different models to the effectiveness estimates.
Model Spearman's rs
(95%confidence interval)
R2-linear regression
ETFP 0.74 (0.69 to 0.77) 0.40
PTSA -0.77 (-0.80 to -0.73) 0.50
PDE -0.78 (-0.81 to -0.74) 0.27
SE&FP 0.54 (0.47 to 0.60) 0.22
SA&P -0.54 (-0.60 to -0.47) 0.22
E&P&EP 0.81 (0.77 to 0.84) 0.65
pain -0.73 (-0.77 to -0.69) 0.54
sunlight exposure 0.36 (0.28 to 0.44) 0.10Minder et al. Health and Quality of Life Outcomes 2010, 8:60
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our intention to develop a measure of phototoxicity per
se e.g. a score enabling the comparison of phototoxicity
intensity among different skin diseases.
The models are based on two components, sunlight
exposure times and pain intensity scores. These compo-
nents were chosen according to a systematic, comprehen-
sive literature review on therapeutic studies in PP [8]. We
assume that daily recording of these components by dia-
ries and/or electronic means are necessary for the gener-
ation of reliable data.
Figure 3 The ETFP model. ETFP is directly related to the effectiveness estimates. The scatter blot displays 490 estimates; the number of visible obser-
vations is reduced by superposition of those observations, as shown by the histogram of residuals.
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Obviously, other variables such as sunlight intensity
and sunlight color influenced by geographical latitude,
season and weather, individual pain sensitivity, protopor-
phyrin concentration in blood, social and psychological
factors may also influence phototoxicity and therefore
inevitably introduce measurement errors to simple mod-
els that are limited to sunlight exposure and pain. The
evaluation of the proposed models faced several prob-
lems: (1) Whereas most PRO's are related to stable dis-
ease situations, PP is characterized by attacks; (2) PRO's
are validated by comparison to another quantitative stan-
dardized measure, which has not been published for PP;
(3) The responsiveness of PRO is validated by an effective
treatment, which is also not available in PP.
T o  o v e r c o m e  s u c h  l i m i t a t i o n s ,  w e  s t a r t e d  f r o m  P P -
patients' expectation of the effectiveness of any medical
treatment, and calculated quantitative correlation factors
of the different models with the patients' expectations.
The three models 'E&P&EP', 'PTSA' and 'ETFP' were
found to best represent these expectations. Distribution
of iso-score lines made plausible that ETFP may show
highest responsiveness.
Internal consistency, one component of model reliabil-
ity, tests for correlations among different items that con-
stitute a PRO. Cronbach's alpha, the measure of internal
consistency, should be above 0.7 to support acceptable
reliability [29]. Cronbach's alpha is -according to our
knowledge - defined for summation scores only. Cron-
bach's alpha of the above mentioned unpublished trial
data was negative (-0.118) when determined from pain,
sunlight exposure and the summation model 'SE&FP'.
The components of our models, sunlight exposure time
and pain score, are complementary rather than highly
correlated information. Therefore, models composed of
these two components represent a multiple cause indica-
tor model rather than a multiple effect indicator [21], as
the items of this model are not interchangeable and thus
have a weak correlation. Consequently, they represent
more than one dimension, which explains the negative
Cronbach's alpha.
The proposed model showed a good inter-rater reliabil-
ity of 0.71, well above the acceptance level of 0.6, indicat-
ing that the patients have very comparable expectations
towards effectiveness of a medical treatment. This find-
ing was surprising, because the disease severity as mea-
sured by the DLQI varied considerably among PP-
patients [7]. DLQI measuring quality of life rather than
PP-related phototoxicity, is not directly comparable with
this model and the DLQI data derived from a much larger
PP-patient sample than in the afamelanotide trial. It
remains to be examined whether DLQI could serve as a
complementary measure to dermal phototoxicity in clini-
cal trials on PP.
The distribution of iso-score lines suggested a higher
responsiveness for the 'ETFP' than for the E&P&EP
model. MID estimated by two different anchors were 15
(10-20) ETFP scores and 6.4 (7.7-15.4) E&P&EP scores. A
comparison of these values to the afamelanotide trial data
will illustrate the potential responsiveness in a clinical
trial. As ETFP-scores exhibited a standard deviation of 53
and a range from 0 to 520 in the afamelanotide trial, the
MIDETFP equals 28% of the standard deviation of the trial
data, and 2.9% of the total range. The MIDE&P&EP was
equal to 96% of the standard deviation and to 5.6% of
total range. These values imply that the sensitivity for
assessment of changes in dermal phototoxicity is higher
for the ETFP model than for the E&P&EP model. The
ETFP model may therefore serve in the future as a tool to
evaluate efficacy of therapeutic interventions in PP, such
as treatment by narrow band UV[30,31], application of
alpha MSH analogues [32,33] or one of the other numer-
ous treatments proposed in PP [8].
Conclusion
Among the six models proposed to assess the effective-
ness of therapeutic interventions in PP the ETFP model
demonstrates the highest sensitivity using the existing
data from a clinical trial of afamelanotide in PP. The
results of this study have provided sufficient validation of
Figure 4 The E&P&EP model fitted to efficacy estimates (A) and a 
graph of residuals versus linear prediction (B).
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Figure 5 ETFP (A), PTSA (B) and E&P&EP(C) in relation to sun exposure time and pain intensity. The lines represent identical values (iso-score 
lines); the exact values are given in the legend on the right side. Examples given in the text serve to improve the readability. ETFP has a better discrim-
inatory power at long exposure times, whereas PTSA has better discriminatory power at short exposure times. E&P&EP has a nearly identical discrim-
inatory power over the whole range of exposure and pain scores.
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the ETFP model that is likely to prove useful in future
clinical trials.
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